JPMorgan Starts Rigel Pharmaceuticals (RIGL) at Overweight
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $42.58 +4.39%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
JPMorgan initiates coverage on Rigel Pharmaceuticals (NASDAQ: RIGL) with an Overweight. PT $14.00.
For more ratings news on Rigel Pharmaceuticals click here and for the rating history of Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $6.97 yesterday.
For more ratings news on Rigel Pharmaceuticals click here and for the rating history of Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $6.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel launches breast cancer drug Veppanu at $29,400 per month
- UBS Starts Schrodinger (SDGR) at Neutral
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
